LN Met 25 Tablet ER is a combination antihypertensive medication containing Cilnidipine 10 mg and Metoprolol Succinate 25 mg in an extended-release formulation. Cilnidipine, a calcium channel blocker of the dihydropyridine class, exerts its effect by inhibiting L-type and N-type calcium channels, leading to vasodilation and reduction of peripheral vascular resistance. Metoprolol Succinate, a selective beta-1 adrenergic receptor blocker, decreases heart rate, myocardial contractility, and cardiac output, contributing to blood pressure reduction. The extended-release formulation ensures a sustained therapeutic effect, promoting better blood pressure control over 24 hours with once-daily dosing. LN Met 25 Tablet ER is indicated for the management of essential hypertension, particularly in patients who require dual therapy to achieve target blood pressure levels. The combination addresses both vascular resistance and cardiac workload, enhancing antihypertensive efficacy while minimizing adverse effects associated with higher doses of individual agents. Caution is advised in patients with bradycardia, heart block, or severe hepatic impairment. Common side effects may include dizziness, fatigue, and peripheral edema. Regular monitoring of blood pressure, heart rate, and renal function is recommended during therapy. LN Met 25 Tablet ER should be used under medical supervision with appropriate dose adjustments based on clinical response.